Note that whereas experimental studies demonstrated a complete reversal of diabetes-induced MNCV and SNCV deficits by a variety of pharmacological agents (reviewed in [36, 37]), the results of clinical trials for example, those of aldose reductase and protein kinase C inhibitors, were quite modest [30, 31, 34, 35]. The gene discussed is AKR1B1; the disease is diabetes mellitus.